Centricity Research
Providing Hope to Present and Future Generations
Centricity Research is committed to the health and wellness of patients living in Nova Scotia.
Why Clinical Research?
Clinical trials are an essential part of the research and development of all pharmaceutical drugs. All medication, whether sold through prescription or over-the-counter, must undergo comprehensive testing to ensure they treat the condition or conditions they were designed and created to treat without significant risk to those taking them.
Each and every trial we conduct is done so under strict guidelines, which are monitored by Health Canada. Health Canada approves the use of investigational medications within clinical trials, before these medications are approved for use by the general public. A Principal Investigator – a medical doctor trained to conduct research trials in a safe, ethical and controlled manner – oversees each of our research trials.
In order to qualify for a trial, participants are screened and must meet a strict criteria. Those participants who qualify to enroll in a trial will be required to attend a variety of appointments and their progress will be carefully tracked. During these visits, participants will work with our clinical staff and investigators. These visits could potentially include questionnaires, blood collection, physical exams, and diagnostic tests.
It should be noted that each participant is fully educated as to what to expect prior to undergoing any trial-related assessments that may be required.
Importance and Benefits of Participation
- Contribution to the future development of medications worldwide
- Access to potential treatment options that is currently not available to the general public
- Constant monitoring and care provided by highly trained professionals
- On-going support provided by clinical research staff
How do I learn more?
If you are interested in learning more about clinical trials, or wish to inquire about out current or future trials, click here to contact us and one of our highly trained staff will be in touch to provide more information.
Recruiting Clinical Trials
Currently Recruiting New Participants
Alzheimer’s Disease Dementia – Biogen – (221-AD-305)
Centricity Research is currently involved in a phase 2 clinical trial with Biogen, to study the efficacy and safety of BIIB080 for treating people with mild cognitive impairment due to Alzheimer’s Disease (AD) or Mild AD Dementia.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 50 to 80 and have been diagnosed with mild cognitive impairment.
The study will run for approximately 105 weeks, or a little over 2 years. Participants who qualify for this study and agree to participate will receive BIIB080 once on day 1 and then once every 12 weeks for up to 72 weeks or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Early Alzheimer’s disease (AD) – AbbVie – (M22-721)
Centricity Research is currently involved in a phase 2 clinical trial with AbbVie, to study the efficacy and safety of ABBV-916 for treating people with early Alzheimer’s Disease.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 50 to 90 and have been diagnosed with stage 3 or Stage 4 AD.
The study will run for approximately 168 days. Participants who qualify for this study and agree to participate will receive once every 4 weeks intravenous (IV) doses of ABBV-916 or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Alcohol Use Disorder (AUD) – Clairvoyant Therapeutics – (CLA-PSY-201)
Centricity Research is currently involved in a phase 2 clinical trial with Clairvoyant Therapeutics, to study the efficacy and safety of psilocybin and psychotherapy for treating people with Alcohol Use Disorder (AUD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 18 to 70 and have been diagnosed with moderate to severe AUD.
The study will run for approximately 40 weeks. Participants who qualify for this study and agree to participate will receive 2 oral doses of 25mg psilocybin capsules or the placebo (a saltwater solution without an active drug). Participation in the study is voluntary, and participants can withdraw at any time.
COVID Vaccine – Moderna – mRNA-1283-P301
COVID-19 is caused by a coronavirus called SARS-CoV-2. Older adults and people who have severe underlying medical conditions like heart or lung disease or diabetes seem to be at higher risk for developing more serious complications from COVID-19 illness.
Qualification: TBD
Compensation: TBD
Study Duration: TBD
Learn more about this study and search protocol mRNA-1283-P301 at clinicaltrials.gov
Post-Traumatic Stress Disorder Study- Apex-002-A01
Centricity Research is currently involved in a phase IIb clinical trial with Apex Labs, LTD, to study the efficacy and safety of psilocybin oral solution in treating depression among adults with post-traumatic stress disorder.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms) of the study drug in patients who are between the ages of 18 and 65 and have been diagnosed with depression and post-traumatic stress disorder.
The study will run for approximately 84 days. Participants who qualify for this study and agree to participate will receive a single dose for 5 consecutive days followed by 2 days off over a 12-week period, for a total of 60 micro-doses. Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease Study- Eli Lilly and Company- J1G-MC-LAKF
Centricity Research is currently involved in a phase 3 clinical trial with Eli Lilly and Company, to study the efficacy and safety of Remternetug IV for the treatment of early symptomatic Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well-known cognitive test scores) of the study drug in patients who are between the ages of 60 to 85 and have AD.
The study will run for approximately 155 weeks. Participants who qualify for this study and agree to participate will receive Remternetug 2300 mg SC, every 12 weeks for 3 doses, or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease Study- Eli Lilly and Company- J1G-MC-LAKD
Centricity Research is currently involved in a phase 3 clinical trial with Eli Lilly and Company., to study the efficacy and safety of Remternetug for the treatment of early Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well known cognitive test scores) of the study drug in patients who are between the ages of 60 to 85 and have AD.
The study will run for approximately 155 weeks. Participants who qualify for this study and agree to participate will receive Remternetug 400mg SC weekly for 36 doses, or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease Study – Merck Sharp & Dohme LLC- MK-1942
Alzheimer’s disease is a type of dementia that impacts approximately 35 million people. Alzheimer’s is a progressive disease that affects an individual’s memory and other brain functions. Common symptoms include confusion and memory loss that disrupt one’s daily life and ability to complete familiar tasks. Other signs of the disease involve difficulty solving problems, poor judgment and decision-making, and changes in personality.
While the risk of developing Alzheimer’s tends to increase with age, the causes of the disease are not fully understood. Current therapies exist; however, research is essential in better understanding the disease and developing improved therapies and treatment options. In this study, we are evaluating the safety and efficacy of an experimental medication as adjunctive therapy in participants with mild to moderate Alzheimer’s disease.
Qualifications:
Ages 55-90
Diagnosed with Alzheimer’s disease
No previous history of stroke or other central nervous system diagnosis
Study Duration: 41 months
Location: Centricity Research, 36 Solutions Drive, Suite 420, Halifax, NS B3S 1B2
Upper Limb Essenial Tremor – AbbVie Inc. – M21-471
Centricity Research is currently involved in a phase 2 clinical trial with Alector Inc., to study the efficacy and safety of AL002 for the treatment of early Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well known cognitive test scores) of the study drug in patients who are between the ages of 50 to 85 and have AD.
The study will run for approximately 96 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks, of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease – Cassava – PTI-125-06
Centricity Research (formerly True North Clinical Research) is currently involved in phase 3 clinical trial with Cassava Sciences, Inc. to investigate the safety and efficacy of Simufilam in patients with mild-to-moderate Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug slows cognitive and functional decline based on cognitive test scores) of the study drug in patients who are between the ages of 50 to 87 with mild-to-moderate AD.
The study will run for approximately 76 weeks, which is about 1.45 years. Participants who consent and qualify for this study will receive either a twice-daily dose of the study drug in tablet form or placebo (which looks like the study drug, but has no active ingredient in it). Participants will have 9 clinic visits and 1 follow-up phone call at the end of treatment. The study involves various tests and MRI scans. Blood samples will be taken at each clinic visit. Participants must have a study partner, who is willing to take part in the study. Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease – Green Memory – GV971-007
Centricity Research is currently involved in a phase 3 clinical trial with Shanghai Greenvalley Pharmaceutical Co., LTD to study the efficacy and safety of GV-971 for the treatment of Mild to Moderate Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who are between the ages of 50 to 85 and have mild to moderate AD.
The study will run for approximately 78 weeks. Participants who qualify for this study and agree to participate will receive a daily dose of either the treatment or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease – INVOKE-2- AL002-2
Centricity Research is currently involved in a phase 2 clinical trial with Alector Inc., to study the efficacy and safety of AL002 for the treatment of early Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well known cognitive test scores) of the study drug in patients who are between the ages of 50 to 85 and have AD.
The study will run for approximately 96 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks, of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s disease – AHEAD 3-45 – BAN2401-G000-303
Centricity Research is currently involved in the AHEAD study, a phase 3 clinical trial with Eisai Inc., to study the efficacy and safety of BAN2401 (Iecanemab), for the investigational treatment of Preclinical Alzheimer’s disease (AD). For clarification, this means the participant is not showing any symptoms of AD.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience-known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on well-known cognitive test scores) of the study drug in patients who are between the ages of 55 to 80.
The study will run for approximately 216 weeks (4 years). Participants who qualify for this study will agree to receive intravenous infusions of the investigational treatment, of either the treatment or placebo (a salt water solution without the active drug). Participation in the study is voluntary, and participants can withdraw at any time.
This study is only recruiting at our New Minas location, Halifax will not be participating in this trial.
Early Alzheimer’s Disease – Alzheon – ALZ-801-AD301– APOLLOE4
Centricity Research is currently involved in a phase 3, multicenter, double-blind, placebo controlled study with Alzheon Inc., to study the effectiveness, safety, and biomarker effects of ALZ-801 for the treatment of early Alzheimer’s disease (AD) for participants who carry two copies of the E4 variant of the Apolipoprotein E gene (APOE4/4).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience -known as side effects) and effectiveness (whether the study drug improves symptoms and how it changes disease progression based on well-known cognitive test scores) of the study drug in patients who are between the ages of 50 to 80.
The study will run for approximately 78 weeks. Participants who qualify for this study and agree to participate will receive daily doses of either the treatment or the placebo (a replica of the study drug with no active ingredients). Participation in the study is voluntary, and participants can withdraw at any time.
Early Alzheimer’s disease – EVOKE/EVOKE plus
Centricity Research is currently involved in the EVOKE and EVOKE plus studies, phase 3 clinical trials with Novo Nordisk A/S, to study the efficacy and safety of semaglutide, for the investigational treatment of Early Alzheimer’s disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience-known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on well-known cognitive test scores) of the study drug in patients who are between the ages of 55 to 85.
The study will run for approximately 173 weeks (3 years, 4 months). Participants who qualify for this study will agree to receive a once-daily dose of the study drug in pill form, of either the treatment or placebo (a pill without the active drug). Participants will have 17 clinic visits and 1 phone call with the study doctor. The study includes various tests and scans. At 10 of the clinic visits, participants will have blood samples taken. Participants must have a study partner, who is willing to take part in the study. Participation in the study is voluntary, and participants can withdraw at any time.
Buena
Centricity Research is involved in a clinical trial with IntelGenX, researching an investigational medication vs placebo in those with mild-moderate Alzheimer’s disease. The investigational medication being studied is a repurposed drug that is already on the market (Montelukast) and the sponsor is looking at the potential of this drug to reduce neuroinflammation in an effort to slow down the progression of memory loss due to Alzheimer’s disease. Participants must already be taking an acetylcholinesterase inhibitor such as Aricept in order to qualify to participate in the trial. This trial is evaluating the relationship between the investigational medication and the cognitive abilities of participants over a 26 week period.
Migraine – AEON Biopharma, Inc. – ABP-20001
Centricity Research is currently involved in a phase 2 clinical trial with AEON Biopharma, Inc. to study ABP-450 for the prevention of migraine headache.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and prevents migraine headache in adult patients) of the study drug in patients who are above the age of 18, with onset of migraine before age 50.
The study will run for approximately 42 weeks. Participants who qualify for this study and agree to participate will receive two sets of injections of either study drug or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.
Essential Tremor – PRAXIS Precision Medicines – PRAX-944-222
Centricity Research is currently involved in a phase 2 clinical trial with Praxis Precision Medicines to study PRAX-944 for the treatment of essential tremor.
The purpose of this study is to assess the safety and tolerability (symptoms and medical problems you may experience – known as side effects) as well as efficacy (how much the study drug improves symptoms of essential tremor) of the study drug in patients who are 18 years of age or older, with onset of tremor at least 3 years ago.
Study participation lasts for up to 98 days. Participants who qualify for this study and agree to participate will be randomly assigned to receive one of 3 dose targets of the study drug or the placebo in tablet form. Participation in the study is voluntary, and participants can withdraw at any time.
Alzheimer’s Disease – Vielight Neuro RX Gamma – P17.03
Recruitment for this trial is currently paused
Centricity Research is currently involved in a clinical trial with Vielight Inc. to study the feasibility, efficacy, and safety of the Vielight Neuro RX Gamma Device for the treatment of moderate to severe Alzheimer’s Disease (AD). The Neuro RX Gamma system is a headset which emits pulsed, near-infrared energy asynchronously through diodes placed on the scalp and inside a nostril.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (whether the device improves symptoms and how it changes disease progression based on well-known cognitive test scores) in patients with Alzheimer’s Disease who are 50 years of age or older.
The study will run for approximately 12 weeks. Participants who qualify for this study and agree to participate will be provided either the Neuro RX Gamma sham device (placebo) or the Neuro RX Gamma active device. The device is to be used for 20-minute sessions 6 days a week at home. There will also be regular follow up visits in the clinic to monitor your health and safety. Participation in the study is voluntary, and participants may withdraw at any time.
Ongoing Clinical Trials
Recruitment Closed
ANAVEX2-73
Centricity Research is currently involved in a phase 2b/3 clinical trial with Anavex Life Sciences Corp. researching an investigational drug for treatment of Early Alzheimer’s Disease (AD) called ANAVEX2-73 (versus a placebo; a treatment that looks like the study drug but is not).
ANAVEX2-71 is an investigational study drug which is being studied in people in who have early AD with mild cognitive (thinking) impairment or mild dementia. This investigational drug is also being studied with patients who have Rett’s Syndrome and for those Parkinson’s Disease and Dementia, however Centricity Research is only involved with the study for those with AD at this time.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.
The study will run for approximately 48 weeks. Participants who qualify for this study and agree to participate will receive a daily dose of either the treatment or the placebo. Participation in the study is voluntary, and participants can withdraw at any time.
Clarity AD
Centricity Research is currently involved in a clinical trial with Eisai Co., Ltd. (known as “Eisai”) researching an investigational drug for early Alzheimer’s disease (AD) called BAN2401.
BAN2401 is what is known as a monoclonal antibody. Antibodies are proteins produced by the immune system that bind to foreign substances in the body called antigens. BAN2401 binds to amyloid in the brain in patients with AD and has been shown to reduce the amount of this abnormal protein. In a different study, BAN2401 slowed the decline in cognition in some people.
The purpose of this study is to assess the safety (symptoms and medical problems you may experience – known as side effects) and efficacy (how much the study drug improves symptoms and reduces amyloid in the brain) of the study drug in patients who have early AD.
Biogen (redosing)
Centricity Research is involved in an open-label study to determine the long-term safety and efficacy of a medication (called aducanumab) in patients who were part of previous studies on that same medication. Aducanumab is an antibody that targets amyloid, a protein that builds up in the brains of people with Alzheimer’s disease.
These studies were originally discontinued based on the belief that the medication didn’t slow the progression of Alzheimer’s disease sufficiently. A re-examination of the data by Biogen (the developer) indicated that those receiving higher doses of the medication showed slower cognitive and functional decline versus those receiving lower doses or the placebo.
Those involved in this current study must have taken part in one of the previous studies.
Trailblazer-ALZ 2 – I5T-MC-AACI
Centricity Research is currently involved in a phase 2 clinical trial with Eli Lilly and Company, to study the efficacy and safety of their investigational drug for the treatment of early Alzheimer’s Disease (AD).
The purpose of this study is to assess the safety (symptoms and medical problems you may experience -known as side effects) and efficacy (whether the study drug improves symptoms and how it changes disease progression based on a well-known cognitive test scores) of the study drug in patients who are between the ages of 60 to 85 and have early AD.
The study will run for approximately 76 weeks. Participants who qualify for this study and agree to participate will receive intravenous injections every 4 weeks of either the treatment or the placebo (a salt water solution without active drug). Participation in the study is voluntary, and participants can withdraw at any time.
Marguerite Road
With Hoffman-La Roche, Centricity Research is involved in a clinical trial researching gantenerumab in patients with mild Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.
Scarlet Road
Centricity Research is involved in a clinical trial with Hoffman-La Roche, researching gantenerumab in patients with prodromal Alzheimer’s disease. This trial is evaluating the relationship between monthly subcutaneous infusions of gantenerumab (a monoclonal antibody) and the cognitive and functional abilities of trial participants. Gantenerumab is designed to remove beta-amyloid plaque from the brain and the theory is that by doing so, they will slow down the progression of Alzheimer’s disease.
Completed Clinical Trials
Centricity Research has proudly participated in many trials that have the potential to impact the lives of hundreds of thousands of people around the globe. Below is a list of some of our completed trails.